Podcasts about Adenocarcinoma

Michelle was diagnosed with Stage 3a Adenocarcinoma of the lung in 2011 with the KRAS mutation and is still alive and living well. ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Bio: Dr Dana Simpler is a primary care doctor who practiced in Baltimore City until retirement in 2022. She is a graduate of University of Maryland Medical School. She became interested in Lifestyle Medicine after reading The China Study by T. Colin Campbell and Prevent and Reverse Heart Disease by Caldwell Esselstyn. After attending many Lifestyle Medicine conferences geared towards practitioners, she incorporated diet and lifestyle recommendations into her regular medical practice. "I found diet changes had a great impact on my patient's health. While not everyone is open to change, it is important for people to at least be advised what they can do to prevent or reverse their medical conditions."

A nurse and mother of four, Marissa was initially diagnosed with stage 3b adenocarcinoma of the lung . She was to be treated with 12 weeks of chemo & radiation, but on day 1 of radiation, a new tumor was found, as well as pleural effusion. She was then given a stage 4 diagnosis, for which there was no treatment. However, Marissa had done genomic testing of her tumor and knew she had a specific mutation which made her eligible for a type of targeted therapy. Within a few days of starting the drug, her cough went away, along with the fluid and the intense pain which had developed. Within 8 weeks, the new tumor was gone and the original tumor was greatly reduced. But, because things had been so dire, she knew she didn't want to rely solely on a drug. Marissa began doing lots of research and came across Radial Remission. She decided to jump all the way in and do all of the healing factors. Today, she has been cancer free for 7 years and credits Radical Remission for her health and longevity. To connect directly with Marissa, please email her at rismoezzi4@hotmail.com ______ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram  YouTube  

Speaking of SurgOnc® has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today®, available on all major podcast platforms. Subscribe today to receive updates on new episode releases.  In this new episode of Speaking of SurgOnc®, Dr. Rick Greene discusses with Dr. Mark Truty the prognosis, and response to neoadjuvant chemotherapy, of resected invasive intraductal papillary mucinous cystic neoplasms compared with de novo pancreatic ductal adenocarcinoma, as reported in their article, "Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma."

In today's episode, supported by Merus, we had the pleasure of speaking with Alison Schram, MD, about the FDA approval of zenocutuzumab-zbco (Bizengri) for patients with previously treated advanced pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) harboring NRG1 gene fusions. Dr Schram is an assistant attending physician at Memorial Sloan Kettering Cancer Center in New York, New York.  On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring an NRG1 gene fusion who have disease progression on or after prior systemic therapy; and adult patients with advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion who have disease progression on or after prior systemic therapy. This regulatory decision was based on findings from the phase 2 eNRGy trial (NCT02912949), in which patients with pancreatic adenocarcinoma (n = 30) achieved an overall response rate (ORR) of 40% (95% CI, 23%-59%), and a duration of response (DOR) that ranged from 3.7 months to 16.6 months. In the NSCLC cohort (n = 64), the (ORR) of 33% (95% CI, 22%-46%), and the median DOR was 7.4 months (95% CI, 4.0-16.6).  In our exclusive interview, Dr Schram discussed the significance of this approval, key efficacy data from the pancreatic cancer and NSCLC cohorts of eNRGy, and the importance of using RNA-based testing to identify patients with NRG1 fusions. 

FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy

On October 18, 2024, the FDA approved zolbetuximab plus fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative, CLDN18.2-positive gastric or GEJ adenocarcinoma. This regulatory decision was backed by findings from the phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials. In SPOTLIGHT, In SPOTLIGHT, patients who received zolbetuximab plus mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin) achieved a median progression-free survival (PFS) of 10.6 months (95% CI, 8.9-12.5) vs 8.7 months (95% CI, 8.2-10.3) in those who received placebo plus chemotherapy (HR, 0.750; 95% CI, 0.601-0.936; 1-sided P = .0053). In GLOW, zolbetuximab plus CAPOX (capecitabine and oxaliplatin) generated a median PFS of 8.2 months (95% CI, 7.5-8.8) vs 6.8 months (95% CI, 6.1-8.1) with placebo plus CAPOX (HR, 0.771; 95% CI, 0.615-0.965; 1-sided P = .0118). In our exclusive interview, Dr Ajani discussed key considerations for the clinical use of zolbetuximab, including its anticipated adverse effect profile and the introduction of CLDN18.2 as a biomarker for assessment prior to treatment initiation.

Ahsen Ustaoglu interviews Dr Matthias Brugel on their targeted screening analysis of pancreatic adenocarcinoma risk with organoclorine pesticides from the PESTIPAC study

The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone in patients with resectable gastric or gastroesophageal junction adenocarcinomas. The multi-continent, Phase III randomized TOPGEAR trial has definitively found no benefit from adding radiation before surgery in terms of overall or progression-free survival. This clear finding was reported simultaneously in the New England Journal of Medicine and at the ESMO 2024 Congress held in Barcelona, Spain. After presenting the findings , first author Trevor Leong, MD, Radiation Oncologist at the Peter McCallum Cancer Centre in Melbourne, Australia, met up with Oncology Times reporter Peter Goodwin.

Dr. Rick Greene discusses with Dr. Dana Dominguez the association of adjuvant chemoradiation in resected biliary cancer with improved overall survival compared to chemotherapy alone, as reported in her article, "Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database.” Article: Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database | Annals of Surgical Oncology (springer.com)

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

Está no ar mais um UroCast ABC! Neste episódio, moderado pelo Dr. Fernando Korkes, convidamos os especialistas Dra. Luciana Schultz e Dr. Caio Suartz para falarem sobre “Adenocarcinoma de úraco e outros adenocarcinomas de bexiga de A a Z”.

Dr. Rick Greene discusses with Dr. Brett Ecker the association between extent of resection and disease-specific survival  in mucinous and non-mucinous appendiceal adenocarcinomas as reported in his article, "Extent of Resection and Long-Term Outcomes for Appendiceal Adenocarcinoma: a SEER Database Analysis of Mucinous and non-Mucinous Histologies.” https://doi.org/10.1245/s10434-024-15233-9

Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the University of Bielefeld in Germany, spoke with Oncology Times reporter Peter Goodwin about his group’s comparison of neoadjuvant therapy using the CROSS (41.4 Gy plus carboplatin/paclitaxel) regimen followed by surgery, with the use of an alternative protocol: perioperative FLOT (5-FU/ leucovorin/oxaliplatin/docetaxel) and surgery, in which chemotherapy is given both before and after curative surgery.

Rick Greene, MD, discusses with Lorenzo Ferri, MD, PhD, the long-term survival outcomes of patients with esophageal and junctional adenocarcinoma treated with neoadjuvant docetaxel-based chemotherapy and en bloc transthoracic esophagectomy. Dr. Ferri is author of, "Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network." Dr. Ferri is Professor of Surgery and Oncology, McGill University; David S. Mulder Chair of Surgery Head, Division of Thoracic and Upper Gastrointestinal Surgery, McGill University Health Centre; and, Director, Upper G.I. Cancer Program, McGill University, Montreal, Canada.

Una ricerca dell’Università di Verona e dell’Istituto oncologico veneto pubblicata su Immunity ha studiato un biomarcatore per l’individuazione precoce del cancro al pancreas e di adenocarcinoma polmonare. A Obiettivo Salute il commento del prof. Vincenzo Bronte, Direttore scientifico dell’Istituto oncologico veneto che ha coordinato la ricerca

Comprehensive, relevant and insightful conversations about health and medicine from the largest healthcare system in the Maryland D.C. region: this is MedStar Health DocTalk.In our latest podcast episode, host Debra Schindler talks with thoracic surgeon Dr. Duane Monteith and gastroenterologist Dr. Dana Sloan for a comprehensive look into esophageal cancer. They discuss everything from early symptoms and risk factors to advanced treatment options like minimally invasive surgery. This episode is packed with valuable insights that could make a significant difference in early detection and treatment. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Did you know that HER2-targeted therapy is an established treatment option for patients with HER2-positive metastatic gastric/gastroesophageal junction (GEJ) cancer? Credit available for this activity expires: 4/16/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000688?ecd=bdc_podcast_libsyn_mscpedu

Did you know that HER2-targeted therapy is an established treatment option for patients with HER2-positive metastatic gastric/gastroesophageal junction (GEJ) cancer? Credit available for this activity expires: 3/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000593?ecd=bdc_podcast_libsyn_mscpedu

Please visit answersincme.com/QHX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal oncology discusses frontline chemoimmunotherapeutic regimens for unresectable advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be better able to: Review guideline-recommended preferred frontline treatment regimens for unresectable advanced gastric or GEJ adenocarcinoma; Discuss clinical profiles of approved and late-stage emerging frontline immunotherapy-based chemotherapy combination regimens for unresectable advanced gastric or GEJ adenocarcinoma; and Outline practical considerations for optimizing treatment with frontline immunotherapy-based chemotherapy combination regimens in patients with unresectable advanced gastric or GEJ adenocarcinoma.

Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer, moderated by Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PostESMO23/Lung).

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Gallbladder Adenocarcinoma⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message

BUFFALO, NY- September 19, 2023 – A new research paper was published in Oncotarget's Volume 14 on September 15, 2023, entitled, “Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma.” Patient-derived organoids (PDOs) and xenografts (PDXs) have been extensively studied for drug-screening. However, their usage is limited due to lengthy establishment time, high engraftment failure rates and different tumor microenvironment from original tumors. In this new study, researchers Dae Won Kim, Francisca Beato, Youngchul Kim, Alexandra F. Tassielli, Ruifan Dai, Jason W. Denbo, Pamela J. Hodul, Mokenge P. Malafa, and Jason B. Fleming from Moffitt Cancer Center developed real time-live tissue sensitivity assay (RT-LTSA) using fresh tumor samples to overcome these limitations. “To overcome the major hurdles of the PDX-based assay, we developed real time LTSA (RT-LTSA) using fresh tumor samples. In this study, we report a reliable and reproducible RT-LTSA with resected fresh tumor samples to predict patients' clinical response to chemotherapy in pancreatic cancer.” Tissue slices from resected pancreatic cancer samples were placed in 96-well plates, and the slices were treated with chemotherapeutic agents. The correlation between the chemo-sensitivity of tissue slices and each patient's clinical outcome was analyzed. The viability and tumor microenvironment of the tissue slices were well-preserved over 5 days. The drug sensitivity assay results were available within 5 days after tissue collection. While all 4 patients who received RT-LTSA sensitive adjuvant regimens did not develop recurrence, 7 of 8 patients who received resistant adjuvant regimens developed recurrence. The researchers observed significantly improved disease-free survival in the patients who received RT-LTSA sensitive adjuvant regimens (median: not reached versus 10.6 months, P = 0.02) compared with the patient who received resistant regimens. A significant negative correlation between RT-LTSA value and relapse-free survival was observed (Somer's D: −0.58; P = 0.016). “RT-LTSA which maintains the tumor microenvironment and architecture as found in patients may reflect clinical outcome and could be used as a personalized strategy for pancreatic adenocarcinoma. Further, studies are warranted to verify the findings.” DOI - https://doi.org/10.18632/oncotarget.28508 Correspondence to - Jason B. Fleming - jason.fleming@moffitt.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28508 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, pancreatic cancer, sensitivity assay, chemotherapy About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Our Surgical Oncology Oral Board Audio Review includes 46 high-yield scenarios that cover all of the SCORE CGSO topics designed for Surgical Oncology Surgeons by Surgical Oncology Surgeons.  Scenarios are 5 to 7 minutes long and include a variety of tactics and styles. If you are able to achieve this level of performance in your preparation you are sure to pass the oral exam with flying colors. The second part introduces high-yield commentary to each scenario. This commentary includes tips and tricks to help you dominate the most challenging scenarios in addition to practical, easy-to-understand teaching that covers the most confusing topics we face as surgical oncology surgeons. We are confident you will find this unique, dual format approach a highly effective way to prepare for the test. Learn more about the course and see all the episode topics here: https://behindtheknife.teachable.com/p/btk-surgical-oncology-oral-board-review-course Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  

Full article: https://www.ajronline.org/doi/10.2214/ajr.23.29674  Peter Gunderman, MD discusses a recent study that finds artificial intelligence can accurately predict the pathology of pure ground glass nodules, at least in the subset of nodules representing variants of adenocarcinoma. 

In this episode of SurgOnc Today, Alexander Parikh MD, MPH, FACS, FSSO, from the University of Texas, San Antonio and Chair of the SSO HPB Disease Site Work Group, and Julie Hallet, MD, M.Sc., FRCSC, from the University of Toronto, and Vice-Chair of the SSO HPB Disease Site Work Group, are joined by Flavio G. Rocha, MD, FACS, FSSO, from the Oregon Health and Science University and Susanne G. Warner, MD, from the Mayo Clinic Rochester. They discuss two important aspects of delivering neoadjuvant therapy for pancreatic adenocarcinoma: the use of staging laparoscopy and the assessment of response. 

Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Kohei Shitara, MD!

A new research paper was published in Oncotarget's Volume 14 on April 15, 2023, entitled, “Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.” Duodenal adenocarcinoma (DA) is a rare malignancy without validated tumor markers. In practice, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) are often used in the management of DA, though their prognostic value is unknown. In this new study, researchers Ellery Altshuler, Raymond Richhart, William King, Mahmoud Aryan, Akash Mathavan, Akshay Mathavan, Keegan Hones, Daniel Leech, Logan Pucci, Joshua Riklan, Pat Haley, Ilyas Sahin, Brian Ramnaraign, Sherise Rogers, Ibrahim Nassour, Steven Hughes, Thomas J. George, and Jesus Fabregas from the University of Florida, University of Florida Health Cancer Center and University of Alabama at Birmingham conducted a single-institution retrospective review including patients diagnosed with biopsy-confirmed adenocarcinoma of the duodenum between 2006 and 2021. “To our knowledge, this is the first study to evaluate the role of tumor markers in patients with DA. In fact, this is the largest single institution study in the US evaluating this disease.” Peri-ampullary tumors were excluded. Levels of CA 19-9 and CEA were collected as continuous variables and were analyzed as binary variables: normal vs. high, using the maximum normal value as a cut-off (normal Ca 19-9

A new research paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells.” Abnormal expression of bicellular tight junction claudins, including claudin-2 are observed during carcinogenesis in human lung adenocarcinoma. However, little is known about the role of tricellular tight junction molecule angulin-1/lipolysis-stimulated lipoprotein receptor (LSR). In the present study, researchers Wataru Arai, Takumi Konno, Takayuki Kohno, Yuki Kodera, Mitsuhiro Tsujiwaki, Yuma Shindo, Hirofumi Chiba, Masahiro Miyajima, Yuji Sakuma, Atsushi Watanabe, and Takashi Kojima from Sapporo Medical University School of Medicine examined expression of claudin-2 in the lung adenocarcinoma tissues and found it was higher than in normal lung tissues, while angulin-1/LSR was poorly or faintly expressed. “We investigated how loss of angulin-1/LSR affects the malignancy of lung adenocarcinoma cell line A549 and normal human lung epithelial (HLE) cells.” The researchers found that the EGF receptor tyrosine kinase inhibitor AG1478 prevented the increase of claudin-2 expression induced by EGF in A549 cells. Knockdown of LSR induced expression of claudin-2 at the protein and mRNA levels and AG1478 prevented the upregulation of claudin-2 in A549 cells. Knockdown of LSR induced cell proliferation, cell migration and cell metabolism in A549 cells. Knockdown of claudin-2 inhibited the cell proliferation but did not affect the cell migration or cell metabolism of A549 cells. The TGF-β type I receptor inhibitor EW-7197 prevented the decrease of LSR and claudin-2 induced by TGF-β1 in A549 cells and 2D culture of normal HLE cells. EW-7197 prevented the increase of cell migration and cell metabolism induced by TGF-β1 in A549 cells. EW-7197 prevented the increase of epithelial permeability of FITC-4kD dextran induced by TGF-β1 in 2.5D culture of normal HLE cells. In conclusion, downregulation of angulin-1/LSR induces malignancy via EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma. “In conclusion, AG1478 and EW-7197 demonstrated potent in vitro anti-lung adenocarcinoma therapeutic activities via LSR/CLDN-2 and the cell metabolism. The use of both AG1478 and EW-7197 may provide a clinical therapeutic approach for lung adenocarcinoma caused by loss of angulin-1/LSR.” Full research paper: DOI: https://doi.org/10.18632/oncotarget.27728 Correspondence to: Takashi Kojima - ktakashi@sapmed.ac.jp Keywords: angulin-1/LSR, claudin-2, cell metabolism, malignancy, lung adenocarcinoma About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

When Anne Shimabukuro, a healthy mother of two, noticed a sharp pain in her left side in 2005, one that manifested itself when she ate, she immediately sought medical attention.  That led to a diagnosis of a malignant tumor in her pancreas.  She wasted no time in getting part of her pancreas removed.  It required a surgical procedure, followed by chemotherapy and radiation therapy.  Anne survived pancreatic cancer and today enjoys a healthy lifestyle.

Full article: https://www.ajronline.org/doi/10.2214/AJR.22.28139  Wenhui Zhou, MD, PhD reviews a recent AJR article which developed and validated a nomogram combining clinical and CT-based radiomics features to differentiate pneumonia-type IMA and pneumonia. This nomogram outperformed radiologist interpretation or clinical factors alone, representing a useful tool in this difficult-to-diagnose disease.

Interview with Marco Del Chiaro, MD, PhD, author of Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. Hosted by Jack West, MD. Related Content: Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy

Garima Suman, MD, discusses her research on early detection of pancreatic cancer using artificial intelligence. Dr. Suman is a radiologist and clinical fellow at the Mayo Clinic in Rochester, Minnesota. The AMA Research Challenge is the largest national, multi-specialty research event for medical students, residents and fellows, and international medical graduates to showcase and present research. Learn more by visiting: https://www.ama-assn.org/about/events/ama-research-challenge

In episode 42 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Dr. Nick Zyromski, a local physician and Professor of Surgery at the IU School of Medicine. Dr. Zyromski is faced with cancer stories every day, as he treats patients with pancreatic, liver and bile duct problems. Tune in as Dr. Zyromski shares the day cancer hit home – when his daughter Sarah was diagnosed with cancer on her sixth birthday – and how community strengthened his family during hard times. Subscribe to the audio version of the Summits Podcast https://summitspodcast.fireside.fm Find out more about the Heroes Foundation https://www.heroesfoundation.org Find out more about The Brookfield Group https://thebrookfieldgroup.com Discover Platform 24 co-working https://www.platform24.co What's your cancer story? Hosted by cancer survivor and philanthropist Vince Todd, Jr., Chairman and Co-Founder of the Heroes Foundation, and Heroes Foundation Board Member Daniel Abdallah, the Summits Podcast is a place for people to share their stories. Everyone has a cancer story. From battling a deadly disease to caring for a loved one, when we rise up and face life's greatest challenges, we see with a new vision, feel with a greater passion, and think with a deeper perspective. Along the way, paths cross, journeys intersect, and missions converge. For Vince Todd, it was his own cancer diagnosis that led him and his wife, Cindy, to launch the Heroes Foundation to provide meaningful support to cancer patients, education to promote cancer prevention, and resources to advance research for a cure. What started with friends and family grew into a community. The Summits Podcast is an extension of that community. Our stories are what bring us together. Artists, athletes, doctors, business people - we're all family members, community leaders, and activists. Everyone has a story. Anyone can inspire. No one battles alone. Join the conversation.

Dr. Rick Greene and Dr. Fadi Dahdaleh discuss the effect of operative approach on overall readiness to commence adjuvant therapy in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy, hypothesizing that minimally invasive pancreaticoduodenectomy improves rates and time to return to intended oncologic therapy compared with open pancreaticoduodenectomy. Dr. Dahdaleh is author of “Surgical Approach does not Affect Return to Intended Oncologic Therapy Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: A Propensity-Matched Study.” Dr. Dahdaleh is an attending surgical oncologist at Northshore-Edward-Elmhurst Health in Chicago and adjunct clinical assistant professor of surgery at Rush Medical College, Chicago, IL.

Rick Greene, MD, discusses with Anne O'Shea, MD, and Timothy Vreeland, MD, the role of neoadjuvant chemotherapy or chemoradiation in the treatment of localized pancreatic adenocarcinoma, and the effect of downstaging on overall survival. Dr. O'Shea and Dr. Vreeland are authors of “Downstaging of Pancreatic Adenocarcinoma with Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival.” Dr. Anne O'Shea is Resident of Surgery in the Department of Surgery at Brooke Army Medical Center, Ft. Sam, San Antonio, TX. Dr. Timothy Vreeland is a Surgical Oncologist also at the Brooke Army Medical Center, Ft. Sam, San Antonio, TX.

In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on:• Identifying patients who may benefit the most from adjuvant osimertinib  • Testing for EGFR mutations in early-stage NSCLC• Critical importance of getting molecular test results before starting immunotherapy• Monitoring cardiac toxicity in patients receiving osimertinib• Key ongoing trials in EGFR-mutated NSCLC for patients with newly diagnosed disease and following progression on osimertinibPresenters:Ryan D. Gentzler, MD, MSAssociate ProfessorDivision of Hematology/OncologyDepartment of MedicineUniversity of VirginiaThoracic Medical OncologistUniversity of Virginia Comprehensive Cancer CenterCharlottesville, VirginiaJonathan Riess, MD, MSAssociate ProfessorDepartment of Internal Medicine/Hematology-OncologyUniversity of California, DavisMedical Director, Thoracic OncologyUniversity of California, Davis Comprehensive Cancer CenterSacramento, CaliforniaLink to full program: https://bit.ly/3DZGzSO  

On today's What to Watch, Drag Race star Kornbread reveals she has been diagnosed with Adenocarcinoma, a type of cancer in the small intestine, but says she will be fine. 40 Don't Worry Darling crew members have issued a joint statement denying bad blood between Olivia Wilde and Florence Pugh on set of the psychological thriller, and Post Malone was hospitalized again for pain in his ribs a week after getting injured on stage. Plus, The Cleaning Lady season 2 is getting complicated, world-class chefs must survive the wilderness in Chefs vs. Wild, and your sweet tooth is indulged with Halloween Cookie Challenge. Learn more about your ad choices. Visit megaphone.fm/adchoices

As a nurse, it was easy for Natasha to think of all the things the almond-sized lump in her armpit could be other than cancer, so she moved along with her busy life. When she realized it was not going away, her doctor sent her for a mammogram. It took six weeks to get there and then her busy schedule delayed it again. The mammogram saw nothing in either breast, but since they could see it and feel it, they sent her for an ultrasound. When the pathologist called, she knew it was bad news before she even answered the phone. Links Support the Breast Cancer Stories podcast https://www.breastcancerstoriespodcast.com/donate Subscribe to our newsletter here: http://eepurl.com/hX12YD About Breast Cancer Stories Breast Cancer Stories follows Natasha Curry, a palliative care nurse practitioner at San Francisco General Hospital, through her experience of going from being a nurse to a patient after being diagnosed with breast cancer. Natasha was in Malawi on a Doctors Without Borders mission in 2021 when her husband of 25 years announced in a text message that he was leaving. She returned home, fell into bed for a few weeks, and eventually pulled herself together and went back to work. A few months later when she discovered an almond-sized lump in her armpit, she did everything she tells her patients not to do and dismissed it, or wrote it off as a “fat lump." Months went by before Natasha finally got a mammogram, but radiology saw nothing in either breast. It was the armpit lump that caught their attention. Next step was an ultrasound, where the lump was clearly visible. One painful biopsy later, Natasha found out she had cancer; in one life-changing moment, the nurse became the patient. This podcast is about what happens when you have breast cancer, told in real time. Host and Executive Producer: Eva Sheie Co-Host: Kristen Vengler Editor and Audio Engineer: Daniel Croeser Theme Music: Them Highs and Lows, Bird of Figment (https://music.apple.com/us/artist/bird-of-figment/1434663902) Production Assistant: Mary Ellen Clarkson Cover Art Designer: Shawn Hiatt Breast Cancer Stories is a production of The Axis. (http://www.theaxis.io/) PROUDLY MADE IN AUSTIN, TEXAS

Today's Episode Dr. Esther G. Chong reviews the case of a 57 year old male who presents with a 1 week history of shortness of breath and a productive cough. He has a history of COPD and has shortness of breath at baseline. Today's Host Dr. Esther G. Chong is a 2nd year hematology/oncology fellow at the University of Loma Linda Medical Center. About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj www.BeyondThePearls.net The Dr. Raj Podcast Dr. Raj on Twitter Dr. Raj on Instagram Want more board review content? Crush Step 1 Step 2 Secrets Physiology by Physeo Step 1 Success Stories The InsideTheBoards Study Smarter Podcast The InsideTheBoards Podcast Study on the go for free! Download the Audio QBank by InsideTheBoards for free on iOS or Android. If you want to upgrade, you can save money on a premium subscription by customizing your plan until your test date on our website! Produced by Ars Longa Media To learn more about us and this podcast, visit arslonga.media. You can leave feedback or suggestions at arslonga.media/contact or by emailing info@arslonga.media. Produced by: Christopher Breitigan Executive Producer: Patrick C. Beeman, MD Legal Stuff InsideTheBoards is not affiliated with the NBME, USMLE, COMLEX, or any professional licensing body. InsideTheBoards and its partners fully adhere to the policies on irregular conduct outlined by the aforementioned credentialing bodies. The information presented in this podcast is intended for educational purposes only and should not be construed as professional or medical advice. Learn more about your ad choices. Visit megaphone.fm/adchoices

Lung Cancer Histology and Staging*Workup for a nodule that is concerning: **Ensure there is a dedicated CT scan of the chest to evaluate **Try to obtain old imaging; the rate of change is important **Can get PET, but even if a lesion if not FDG-avid, but growing quickly we should consider biopsy anyway**Referral to pulmonary medicine, who can assist with biopsy and also regional lymph node evaluation (important – more below)**PFTs are often ordered because it provides information about lung function in anticipation of possible surgery for treatment Lung Cancer Histology: *Non-small cell lung cancer (NSCLC)**Umbrella term for a variety of cancers**Increased risk in smokers**More common types: ***Adenocarcinoma (~50% of all lung cancers)****Most common overall; cancer of the mucus producing cells****IHC: TTF-1, NapsinA, CK7 positive***Squamous Cell Carcinoma (22.7%)****More often seen in patients with a smoking history ****IHC: p63 positive and cytokeratin pearls***Remaining ~15% are the other types of lung cancer / mixed histologies**Small cell lung cancer (SCLC)***Neuroendocrine tumor with very different pathology***Much more aggressive than NSCLC***Oncologic emergency***IHC: Chromogranin and synaptophysin positive IHC pearls: TTF-1 usually means lung cancer (but can be negative in squamous cell lung cancer). This will be important in the future (we promise :])*Staging for NSCLC:**Nodal evaluation: lymph node evaluation is part of the workup for NSCLC**Single digit = central/mediastinal nodes (higher risk)**Double digit = peripheral/hilar/intrapulmonary lymph nodes (lower risk)**“R” vs. “L” is direction *Pearl: Why is this important? If there is nodal involvement, systemic therapy is going to be necessary *Putting it all together: **T: Tumor size: T1-4**N: Nodal involvement***N0: no nodal involvement ***N1: Nodes closest to the primary tumor (double digits)****Ipsilateral peribronchial, hilar, intrapulmonary ***N2: Further away (single digit)****Ipsilateral mediastinal and/or subcarinal LN***N3: Contralateral any node or supraclavicular LN **M: Metastasis – in lung cancer, patients with certain patterns of metastatic disease are still curable! ***M0: no mets***M1a: Contralateral lobe, pleural effusion or pericardial effusion à these are generally still curable!***M1b: single site of metastatic disease à these are generally still curable!***M1c: multiple sites of metastatic disease à these are generally not curable*Staging for SCLC: **Limited stage - meaning it can fit in “one radiation field”**Extensive stage - does not fit in “one radiation field”*Once lung cancer is diagnosed:**Go to NCCN to learn the flow of ongoing management**Complete staging (if not already done):***CT C/A/P (don't necessarily need if a PET scan is done)***PET Scan***MRI brain à in general this is needed, but there are some exception to this (see NCCN)**Referral to pulmonary for nodal evaluationReferences: NCCN.orghttps://doi-org.proxy.library.vanderbilt.edu/10.1016/j.semcancer.2017.11.019-Article about IHC markers for lung cancer Please visit our website (TheFellowOnCall.com) for more information Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Dr. Robert Hsu from the Department of Internal Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center and Hospital, University of Southern California, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas.” DOI - https://doi.org/10.18632/oncotarget.28132 Correspondence to - Jorge J. Nieva - jorge.nieva@med.usc.edu Abstract Cancer/testis antigens (CTAs) are strongly expressed in some solid tumors but minimally expressed in normal tissue, making them appealing therapeutic targets. KK-LC-1 (CXorf61) has cytoplasmic expression in gastric, breast, and lung cancer. We characterized the molecular subtypes of non-small cell lung cancer (NSCLC) expressing KK-LC-1 to inform rational clinical trials of T-cell receptor therapy (TCR-T) targeting KK-LC-1. 9790 NSCLC tumors that underwent whole transcriptome sequencing (Illumina NovaSeq) and NextGen DNA sequencing (NextSeq, 592 Genes and NovaSEQ, WES) at Caris Life Sciences (Phoenix, AZ) were analyzed. Tumors were split into quartiles based on KK-LC-1 expression and pathological and molecular differences were investigated. Adenocarcinoma had significantly higher KK-LC-1 expression than squamous cell carcinoma (median, 3.25 vs. 1.17 transcripts per million (TPM), p < 0.0001). Tumors with the highest quartile of KK-LC-1 expression had a greater proportion of tumors with high tumor mutation burden (TMB) (≥10 mutations per megabase; 44% vs. 28% in Q1, p < 0.001). Increased KK-LC-1 expression was associated with increased M1 macrophage abundance. Higher levels of KK-LC-1 expression were seen in pan-wild type and KRAS mutated tumors and associated with high TMB. TCR-T therapy directed against KK-LC-1 should be considered in patients whose clinical features reflect these characteristics. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28132 Press release - https://www.oncotarget.com/news/pr/kita-kyushu-lung-cancer-antigen-kk-lc-1-expressing-carcinomas/ Keywords - lung cancer, tumor microenvironment, diagnostic biomarkers, biomarkers for immunotherapy, cancer testis antigen About Oncotarget Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

That's right folks, we do anal gland removals! An entire episode dedicated to butt stuff. Did we mention we talk about butts? If buttock-related surgeries give you the heebie-jeebies, seek cover no longer!   Twitter: @AllVetsAreOff Merch: https://allvetsareoff.threadless.com/ Email: Allvetsareoff@gmail.com  

Join Yvonne Brandenburg, RVT, VTS SAIM and Jordan Porter RVT, LVT, VTS SAIM as we talk with Danielle DeCormier, LVT, VTS (Onco) and Jenny Fisher, RVT, VTS (Onco) Apocrine gland anal sac adenocarcinoma (AGASACA): definitely worth every patient having a rectal exam to find these early. Thanks so much for tuning in. Join us again next week for another episode!  ​Want to earn some RACE approved CE credits for listening to the podcast? You can earn between 0.5-1.0  hour of RACE approved CE credit for each podcast episode you listen to.  Join the Internal Medicine For Vet Techs Membership to earn and keep track of your continuing education hours as you get your learn on! Join now! http://internalmedicineforvettechsmembership.com/ Get Access to the Membership Site for your RACE approved CE certificates Sign up at https://internalmedicineforvettechsmembership.com  Get Access to the Technician Treasure Trove  Sign up at https://imfpp.org/treasuretrove  Thanks for listening!  – Yvonne and Jordan 

In this episode, Dennis M. Bier MD Young Career Editor Kevin C. Klatt, PhD, RD speaks with first author, Sachelly Julián-Serrano and leader author, Rachael Z Stolzenberg-Solomon, of the recently published AJCN manuscript “Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies”. In this episode, we dive into genetic epidemiology approaches, iron metabolism, and the risk of PDAC with our 2 guest authors from the Division of Cancer Epidemiology and Genetics at the National Cancer Institute.Be sure to connect with us on twitter ( Sachelly Julián-Serrano: @sachellyjs; AJCN: @AJCNutrition; Dr. Klatt: @kcklatt. Find all of the publications from the American Society for Nutrition (@nutritionorg; @jnutritionorg) at our website: https://nutrition.org/publications/.

All star mentor/mentee pair from the University of Kentucky, Dr. Aman Khurana and medical student Emad Chishti join me. They demystify congenital urachal anomalies with a fabulous case explaining calcs, mucin and more. Case Images here. Full transcript here. Abbreviated transcript below....   Lindsey Negrete: introduces the episode Emad Chishti: vesicourachal diverticulum with urachal adenocarcinoma. The urachus is the fetal derivative of the allantois, which is a channel between the embryonic bladder and umbilicus. Usually, it involutes before birth and forms the median umbilical ligament, but when it doesn't close off properly, a blind pouch-like structure remains connected to the bladder forming a diverticulum.  62-year-old male with a history of kidney stones presented with right flank, suprapubic, and inguinal pain of a few weeks duration Aman Khurana: CT/US/MR demonstrating a bladder diverticulum within the anterosuperior part of the bladder dome with a soft tissue density protruding from the diverticulum into the bladder cavity. Patient underwent a resection of the bladder mass with pathology consistent with invasive, moderately differentiated mucinous adenocarcinoma with signet ring cell features consistent with urachal carcinoma. Repeat MR with persistent contrast enhancement with concern for residual tumor. Patient underwent second surgery again confirming mucinous adenocarcinoma. Emad Chishti: question about peripheral calcification helping with the diagnosis?  Aman Khurana: mucinous loves to calcify, calcifications can be punctate, stippled, curvilinear Emad Chishti: other than a diverticulum, are there any other congenital abnormalities associated with urachus? Aman Khurana: four types of congenital urachal abnormalities: patent urachus, urachal sinus, urachal cyst, vesicourachal diverticulum Emad Chishti: multiple-choice question, On histology, the cells lining urachal neoplasms would most likely best resemble which of the following? Answer: intestinal epithelium, the majority of urachal neoplasms are adenocarcinomas Aman Khurana: on MRI, these tumors do look mildly T2-hyperintense because of the mucin producing cells Lindsey Negrete: pattern of growth for urachal carcinoma versus vesical tumor. Differential diagnosis. Call for companion cases. Calling all mentor/mentee pairs to submit cases together! It's really fun!

It's been a while! I think we will call this the second season as it seems fitting as I head into another season of battling cancer. Devastated and angry are just two of the words that come to mind. But also with that come to surrender and faith. Thank you for being on the journey with me so far. Tag along as I fight cancer again. If you enjoyed this episode, make sure and give us a five star rating  and leave us a review on iTunes, Podcast Addict, Podchaser and Castbox. Sign up for the next DAC Bootcamp Follow me on Social Media:Amy on IGAmy on Facebook Resources:AmyLedin.comLean Bodies Consulting (LBC)LBC University